Naurif Tablet

About Naurif 1 mg Tablet

Naurif 1 mg Tablet is a medicine used to prevent nausea and vomiting caused by cancer chemotherapy and radiation treatment. It contains granisetron and is made by Square Pharmaceuticals PLC.

There are 2 brands of Granisetron listed in Bangladesh. 1 of them has a lower unit price than Naurif.

What is Naurif 1 mg Tablet?

Naurif 1 mg Tablet is a supportive care medicine for people receiving cancer treatment. It helps prevent the nausea and vomiting that can follow chemotherapy, including strong regimens, and radiation therapy. The active ingredient, granisetron, works by blocking a natural substance in the body that triggers the vomiting reflex. It belongs to a group called serotonin receptor antagonists. The tablet is available as 1 mg strength in a pack of 2 x 10 tablets. The doctor decides whether it is suitable and how it should be used alongside cancer treatment.

Uses of Naurif

Naurif 1 mg Tablet is used to prevent nausea and vomiting linked to emetogenic cancer chemotherapy, including high-dose cisplatin, and to radiation treatment such as total body irradiation and fractionated abdominal radiation. It is given on the days chemotherapy or radiation is scheduled. It is not intended for continued use when cancer treatment is not being given. Ask your doctor if you are unsure why it has been prescribed.

How to use Naurif

Take Naurif 1 mg Tablet exactly as your doctor tells you. The doctor decides the dose, how often to take it, and how many days you need it. Swallow the tablet with water. If you are unsure when to take it around your chemotherapy or radiation session, ask your doctor or pharmacist. Do not change the dose on your own, and do not stop unless your doctor advises it.

Side effects of Naurif

Like all medicines, Naurif 1 mg Tablet can cause side effects. Common ones include headache, trouble sleeping, constipation and diarrhoea. Some people may have changes in liver enzyme tests, heart rhythm changes, slow heartbeat, palpitations, chest pain, or feel sick. Tell your doctor if you notice any side effect or if it worries you. Your doctor can advise whether you need any check-ups while taking this medicine.

Safety and precautions

Before taking Naurif 1 mg Tablet, tell your doctor if you have heart problems, are having chemotherapy that can affect the heart, or have electrolyte abnormalities. It may hide signs of bowel blockage or stomach swelling. Tell your doctor about all other medicines you take, as some can interact with granisetron. It is pregnancy category B; use in pregnancy only if clearly needed. It is not known if it passes into breast milk, so caution is needed while breastfeeding. Ask your doctor first if you are pregnant, planning pregnancy or nursing.

Frequently asked questions

What is the price of Naurif 1 mg Tablet?

The listed price is ৳ 28.19.

What does the generic name granisetron mean?

Granisetron is the active ingredient in Naurif 1 mg Tablet. It is a serotonin receptor antagonist, meaning it blocks a natural substance called serotonin that can trigger nausea and vomiting, especially after cancer treatment.

What is Naurif 1 mg Tablet used for and what kind of medicine is it?

It is a supportive care medicine used to prevent nausea and vomiting caused by emetogenic cancer chemotherapy and radiation therapy. It contains granisetron and belongs to a group of medicines called serotonin receptor antagonists.

How should Naurif 1 mg Tablet be taken?

Take it exactly as your doctor prescribes. The doctor decides the dose, how often and for how long you take it, based on your cancer treatment. Swallow with water. Ask your doctor or pharmacist if you are unsure about timing or dose.

Indications

Granisetron Tablet is indicated for Nausea and vomiting associated with initial and repeat course of emetogenic cancer therapy, including high dose of cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation.

Granisetron ... Read moreGranisetron Tablet is indicated for Nausea and vomiting associated with initial and repeat course of emetogenic cancer therapy, including high dose of cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation.

Granisetron Injection is indicated for: The prevention of nausea and vomitng associated with initial and repeat courses of emetogenic cancer chemotherapy, therapy including high dose cisplatin. The prevention and treatment of post operative nausea and vomiting.

Pharmacology

Granisetron is a highly selective 5-HT3 receptor antagonist with little or no affinity for other serotonin receptors. It blocks serotonin peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone.

Serotonin receptors of the 5-HT3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy that induces vomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT3 receptors. This evokes vagal afferent discharge, inducing vomiting. Animal studies demonstrate that, in binding to 5-HT3 receptors, granisetron blocks serotonin stimulation and subsequent vomiting after emetogenic stimuli such as cisplatin. In the ferret animal model, a single granisetron injection prevented vomiting due to high-dose cisplatin or arrested vomiting within 5 to 30 seconds.

In most human studies, granisetron has had little effect on blood pressure, heart rate or ECG. No evidence of an effect on plasma prolactin or aldosterone concentrations has been found in other studies.

Dosage & Administration

Tablet-

Emetogenic Chemotherapy: The recommended adult dosage of oral Granisetron is 2 mg once daily or 1 mg twice daily. In the 2 mg once-daily regimen, two 1 mg tablets is given up to 1 hour before chemotherapy. In the 1 mg twice-daily regimen, the first 1 mg tablet is given up to 1 hour before chemotherapy, and the second tablet is given 12 hours after the first. Either regimen is administered only on the day(s) chemotherapy is given. Continued treatment, while not on chemotherapy, has not been found to be useful.

Injection-

Chemotherapy Induced Nausea and Vomiting:
  • Adults: The recommended dosage for Granisetron Injection is 10 mcg/kg administered intravenously within 30 minutes before initiation of chemotherapy, and only on the day(s) chemotherapy is given. Granisetron Injection may be administered intravenously either undiluted over 30 seconds, or diluted with 0.9% Sodium Chloride or 5% Dextrose and infused over 5 minutes. As a general precaution, Granisetron Injection should not be mixed in solution with other drugs.
  • Paediatric Patients: The recommended dose in paediatric patients 2 to 16 years o f age is 10 mcg/kg. Paediatric patients under 2 years o f age have not beenstudied.
  • Geriatric Patients, Renal Failure Patients or Hepatically Impaired Patients: No dosage adjustment is required.
Treatment of Postoperative Nausea and Vomiting:
  • Adults: The recommended dosage for prevention of postoperative nausea and vomiting is, a single dose of 1 mg of Granisetron should be diluted to 5 ml andadministered as a slow intravenous injection (over 30 seconds). Administration should be completed prior to induction of anesthesia. The recommended dosage for the treatment of nausea and vomiting after surgery is 1 mg of Granisetron undiluted, administered intravenously over 30 seconds.
  • Paediatric Patients: Safety and effectiveness of Granisetron Injection have not been established in paediatric patients for the prevention or treatment of post operative nausea or vomiting.
  • Geriatricpatients, Renal Failure Patients or Hepatically Impaired Patients: No dosage adjustment is required.

Interaction

Induced metabolism with phenobarbital. Risk of serotonin syndrome with other serotonergic agents e.g. SSRIs, and serotonin and norepinephrine reuptake inhibitors (SNRIs). Altered clearance with CYP enzyme inducers or inhibitors. Concomitant use with drugs known to prolong QT interval may result in clinical consequences.

Contraindications

Granisetron is contraindicated in patients with known hypersensitivity to granisetron.

Side Effects

Headache, insomnia, constipation, diarrhoea, elevated hepatic transaminases; QT prolongation; bradycardia, palpitations, sick sinus syndrome, chest pain. Application site reactions (transdermal): Rash, pain, erythema, pruritus, irritation, burn, vesicles, urticaria, discolouration; patch non-adhesion.

Pregnancy & Lactation

Pregnancy Category B. No evidence of impaired fertility or harm to the animal fetus have been found. However, this drug may be used in pregnancy only if clearly needed. It is not known whether granisetron is excreted in human milk. So cautions hould be exercised when granisetron is administered to a nursing mother.

Precautions & Warnings

Patient with cardiac co-morbidities, on cardiotoxic chemotherapy and/or woth concomitant electrolyte abnormalities. May mask progressive ileus and/or gastric distention. Childn. Pregnancy and lactation.

Storage Conditions

Store between 15-30°C. Protect from light.

Alternative brands of Granisetron

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.